AURIGENE ONCOLOGY LIMITED
Location
Karnataka
Founded
2001-08-10
Website
Risk Signals
7 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about AURIGENE ONCOLOGY LIMITED
Live alerts from global media, monitored by Business Radar
2024-09-16 (expresshealthcare.in)
ICMR signs agreements for first-in-human clinical trials of four new molecules –
ICMR partners with industry leaders for trials on molecules targeting multiple myeloma, Zika, influenza, and chronic lymphocytic leukaemia
Read more
(bioworld.com)
Aurigene Oncology reports potent and selective degraders of SMARCA2 and SMARCA4 as cancer therapeutics |
At the recently concluded AACR-NCI-EORTC meeting in Boston, Aurigene Oncology Ltd. reported the identification and optimization of paralogue selective degraders of SMARCA2 (AU-SM2-1) and SMARCA4 (AU-SM4-1), developed using the ALMOND-guided designing strategy, for the potential treatment of various cancers.
Read more